North American Vaccine, Abbott deal

The companies reached an agreement in principle for Abbott to market NVX's diphtheria, tetanus and whooping cough vaccine (DTaP) following FDA approval. NVX could receive up to $42 million in payments, including equity investments, license and development payments and milestones, as well as revenues from sales.

Abbott also would be able to market combination vaccines now under development at NVX, which combine DTaP with antigens to prevent polio and haemophilus influenza type b. ...